Latest Content

Jaypirca Plus Venclexta With or Without Rituxan May Be Beneficial in r/r CLL

October 10th 2024, 1:00pm

By Alex Biese

Article

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

FDA Clears Application to Study Stem Cell-Based Treatment for High-Grade Glioma

October 9th 2024, 9:00pm

By Darlene Dobkowski, MA

Article

CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly diagnosed high-grade glioma.

Ninlaro Combo Delays Post-Transplant Progression in Relapsed Myeloma

October 9th 2024, 7:00pm

By Alex Biese

Article

Ninlaro, Thalomid and dexamethasone followed by Ninlarlo maintenance may improve durability of response in myeloma after stem cell transplantation relapse.

Being Unprepared May Open The Door To Life-Changing Lessons With Stage 4 Cancer

October 9th 2024, 5:00pm

By Martha Carlson

Article

Martha Carlson shares her experience of overcoming her fears and embarking on a whitewater rafting adventure despite her stage 4 cancer diagnosis.

Brukinsa Recommended Versus Imbruvica in R/R CLL, SLL

October 9th 2024, 3:00pm

By Ashley Chan

Article

Patients with relapsed or refractory CLL or SLL may benefit from receiving Brukinsa instead of Imbruvica, as Brukinsa demonstrated superior effectiveness.

Lymph Node Removal May Be Avoidable in Some With Breast Cancer

October 9th 2024, 1:00pm

By Alex Biese

Article

A study found that nearly all older patients with ER-positive DCIS could have avoided lymph node removal, researchers have stated.

ctDNA Testing Helps Predict Recurrence in Merkel Cell Carcinoma

October 8th 2024, 9:00pm

By Ashley Chan

Article

Among patients with Merkel cell carcinoma, using ctDNA testing may help with watching the disease for potential recurrences and those who are high-risk.

Revumenib May Have Benefits for Patients with R/R KMT2Ar Acute Leukemia

October 8th 2024, 7:00pm

By Alex Biese

Article

More than 60% of patients with relapsed or refractory KMT2Ar acute leukemia responded to the menin inhibitor revumenib.

You Can’t Spell Patient Without AI

October 8th 2024, 5:00pm

By Burt Rosen

Article

Cancer is complicated, especially with multiple diagnoses, oncologists, tests and integrative treatments, but AI can be a helpful tool.

Lazcluze Shows Central Nervous System Activity In EGFR-Variant NSCLC

October 8th 2024, 3:00pm

By Spencer Feldman

Article

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal metastases in patients with EGFR-variant NSCLC.

First Patient With Ovarian Cancer Receives Peptide-Drug Conjugate in Study

October 8th 2024, 1:00pm

By Darlene Dobkowski, MA

Article

This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.

High vs Low Dose of Vitamin D May Not Impact Treating mCRC

October 7th 2024, 9:00pm

By Spencer Feldman

Video

For patients with metastatic colorectal cancer, adding a higher dose proves just as effective as the standard dose of vitamin D3, despite one exception.

Chemotherapy, Chemoradiotherapy May Improve Esophageal Cancer Survival

October 7th 2024, 7:00pm

By Alex Biese

Article

For patients with adenocarcinoma of the esophagus and esophagogastric junction, chemoradiotherapy and chemotherapy improved survival versus surgery alone.

My Bitter Chemotherapy Pills for Chronic Lymphocytic Leukemia

October 7th 2024, 5:00pm

By Chester Freeman

Article

I’ve recently started on chemotherapy pills instead of infusions and the bitterness reminds me to accept not only the bitterness of the pill, but in life too.

Keytruda Plus Chemo New Standard of Care in Pleural Mesothelioma

October 7th 2024, 3:00pm

By Ashley Chan

Article

First-line Keytruda plus chemotherapy is the new standard of care for patients with advanced pleural mesothelioma after the previous treatment strategy of chemotherapy alone.